Authors

Latest:

Dr. Raizer Discusses Proton Therapy for Glioma

Jeffrey J. Raizer, MD, Co-Director, Northwestern Brain Tumor Institute, Professor in Neurology, Ken and Ruth Davee Department, Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses a study that analyzed the overall survival and toxicity of proton therapy for large-volume re-irradiation for recurrent glioma.

Jeffrey Jones, MD

Latest:

Dr. Jeffrey Jones on NCCN Recommendations for Relapsed Patients With CLL

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses NCCN recommendations for treatment of relapsed patients with chronic lymphocytic leukemia (CLL).

Jeffrey Jones, MD, MPH

Latest:

Dr. Jones on Studying Venetoclax in R/R CLL

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discuss the interest in studying venetoclax (Venclexta) in a phase II study for patients with chronic lymphocytic leukemia (CLL).

Jeffrey Lancet, MD

Latest:

Dr. Lancet on CPX-351 Compared to Chemotherapy for Older Adults With AML

Dr. Lancet of Moffitt Cancer Center explains the use of CPX-351 treatment compared to induction chemotherapy, for older adult patients with acute myeloid leukemia.

Jeffrey Lancet, MD, Moffitt

Jeffrey M. Clarke, MD

Latest:

Dr. Clarke on Available EGFR TKIs in Frontline Treatment of EGFR+ NSCLC

Jeffrey M. Clarke, MD, assistant professor of medicine, Duke Cancer Institute, discusses the available EGFR TKIs in the frontline setting for the treatment of patients with EGFR-positive non–small cell lung cancer (NSCLC).

Jeffrey M. Fowler, MD

Latest:

Dr. Fowler on Patient Eligibility for Cytoreductive Surgery in Ovarian Cancer

Jeffrey M. Fowler, MD, discusses patient eligibility for cytoreductive surgery in newly diagnosed ovarian cancer.

Jeffrey M. Friedman, MD, PhD

Latest:

PrimeMD, a Pain Reporting Smartphone Application for Patients Undergoing Head and Neck Radiation

A feasibility study of a smartphone application that patients undergoing radiation therapy for head and neck cancer can use to regularly report mucositis symptoms.

Jeffrey M. Holzbeierlein, MD

Latest:

Dr. Holzbeierlein on the Management of Bladder Cancer Guidelines

Jeffrey M. Holzbeierlein, MD, professor, director of Urologic Oncology, Department of Urology, University of Kansas Medical Center, discusses the management guidelines for patients with bladder cancer.

Jeffrey M. Trent, MD, PhD

Latest:

Dr. Jeffrey Trent on the Melanoma Dream Team

Jeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute, discusses the Stand Up to Cancer-Melanoma Research Alliance Dream Team.

Jeffrey M. Vainshtein, MD

Latest:

Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer: Implications for Radiotherapy Target Volume Delineation

The ipsilateral parotidean nodes may be at risk of metastatic involvement when bulky ipsilateral level II metastases and multilevel nodal disease are co-existent, possibly due to retrograde lymphatic drainage.

Jeffrey N. Weitzel, MD

Latest:

Dr. Weitzel on the Identification of Li-Fraumeni Syndrome

Jeffery Weitzel, MD, discusses the identification of Li-Fraumeni syndrome.

Jeffrey R. Infante, MD

Latest:

Dr. Infante on AM0010 in Patients With RCC

Jeff R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase I study of the novel immunotherapy agent AM0010 and its early promise in patients with renal cell carcinoma.

Jeffrey S. Weber, MD, NYU Langone Medical Center

Jeffrey Weber, MD, PhD, NYU Langone Health, Perlmutter Cancer Center

Latest:

Rapids Readouts: Phase 3 CheckMate 238 Trial

Jeffrey S. Weber, MD, PhD, Laura

Jeffrey S. Weber, MD, PhD, NYU Langone Health

Latest:

Dr Weber on the Background of the KEYNOTE-942 Trial in High-Risk Melanoma

Jeffrey S. Weber, MD, PhD, discusses the background for the KEYNOTE-942 trial, which was conducted in resected high-risk melanoma.

Jeffrey S. Weber, MD, PhD, NYU Langone Medical Center

Jeffrey Weber, MD, PhD, NYU Langone Medical Center

Jeffrey Wolf, MD

Latest:

Dr. Wolf Discusses High-Risk Multiple Myeloma

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses high-risk multiple myeloma.